Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Lilly, Novartis join drugmakers in scaling back operations in Russia

Published 03/15/2022, 10:29 AM
Updated 03/15/2022, 04:31 PM
© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar
LLY
-
PFE
-
JNJ
-
ABT
-
ABBV
-
BAYRY
-

(Reuters) -A growing number of drugmakers including Eli Lilly (NYSE:LLY) and Co, Novartis and Abbvie Inc are scaling back business in Russia after Moscow's invasion of Ukraine, but still pledge to continue supplying critical medicines.

U.S. drugmaker Lilly said it will send medicines for urgent medical conditions such as cancer and diabetes. It is suspending sales of what it called "non-essential medicines" as well as all investments and promotions. It also will not start any new clinical trials there.

Swiss drugmaker Novartis also said it would stop investments, marketing activities there and all scientific events organized by the company or external parties in Russia.

U.S. drugmaker AbbVie (NYSE:ABBV), which owns blockbuster wrinkle treatment Botox, said it has temporarily suspended operations for all its aesthetics products in the country.

Johnson & Johnson (NYSE:JNJ) Inc said it was stopping enrollment in Ukraine, Russia and Belarus as well as any openings of new sites, but was committed to providing essential health products.

On Monday, Pfizer Inc (NYSE:PFE), Germany's Bayer (OTC:BAYRY) and Abbott Laboratories (NYSE:ABT) had pulled back from non-essential spending in the country. Pfizer and Bayer said they would maintain a supply of medicines to Russia.

Western companies have come under pressure to leave Russia, but the healthcare sector has not pulled out because medicine and medical devices and equipment are considered necessary for humanitarian reasons and are excluded from sanctions.

"While it is good to see large corporations, including in the pharmaceutical space, take a proactive stand against war and aggression, any step to suspend medical supplies, even for non-essential items, could end up putting the health of patients in Russia at risk," said Anant Bhan, a global health and bioethics researcher.

Getting supplies in has already become tougher. Sanctions have cut off Russian banks from the international financial system, while shipping companies have halted services to the country, interrupting delivery of medical supplies.

© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar

In a post titled "Lilly and Lilly Foundation Provide support for People in Ukraine" on its website, Lilly said any profit from continued sales in Russia will be donated to organizations dedicated to humanitarian relief.

Lilly is the first to exclude drugs it designates as "non-essential". The company told Reuters in an email that an example of a non-essential medicine was Cialis, a branded erectile dysfunction treatment available from other sellers as a generic drug. It did not disclose specific treatments affected by the decision.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.